Browse all our past articles

For hundreds of years the UK has been at the forefront of medical research and technology, now Royal Mail celebrates the work of six scientists and their life-changing discoveries.

The increased need for real-time data management and the improved receptiveness of a technology to monitor patients effectively are driving the markets for data management systems (DMSs) for patient monitoring in Europe.

There is much current interest in the entirely subcutaneous implantable cardioverter-defibrillator (S-ICD) which is heralded as a major advance for the prevention of sudden cardiac death in selected patients.

The National Institute for Health and Clinical Excellence (NICE) has issued its final appraisal determination on dronedarone (Multaq) recommending the drug as an option for non-permanent atrial fibrillation (AF) in selected patients. (1)

Great Ormond Street Hospital for Children NHS Trust, has successfully used the new Affinity PixieTM paediatric oxygenator from Medtronic in its first clinical cases for infant and paediatric heart surgery.

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, has announced that it has been designated a nominated supplier by the British Heart Foundation (BHF) for its ZOLL (Automatic external defibrillator) AED Plus® and ZOLL AED Pro®.

“Worldwide, strokes are the most common cause of death. This makes it a top priority for medicine to expand prevention in this area,” said Prof. Dr. Karl Max Einhäupl, from the University Clinic Charité in Berlin, who is co-chair of the Annual Meeting of the European Neurological Society (ENS) which took place in Berlin recently.

Over 200 million people fly through British airports each year – many with heart disease. How do these patients with heart disease know whether they can fly safely or whether flying might pose risks to their health?

The initiation of a multinational, randomized, double-blind Phase IIIb trial, PALLAS to assess the potential clinical benefit of Multaq® (dronedarone) in over 10,000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events, was announced during the Heart Rhythm Society’s 31st Annual Scientific Sessions.

Allopurinol, which has commonly been used to treat gout for over 40 years, has had a new lease of life recently as it may help preserve renal function, according to an analysis appearing in the Clinical Journal of the American Society of Nephrology (CJASN) (1) and it is also potentially a drug for treatment of angina.